Tributary Capital Management LLC Trims Stake in Integer Holdings Corporation (NYSE:ITGR)

Tributary Capital Management LLC trimmed its holdings in Integer Holdings Corporation (NYSE:ITGR - Free Report) by 3.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 278,115 shares of the medical equipment provider's stock after selling 9,410 shares during the quarter. Integer accounts for approximately 2.9% of Tributary Capital Management LLC's investment portfolio, making the stock its biggest holding. Tributary Capital Management LLC owned 0.80% of Integer worth $32,820,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Proficio Capital Partners LLC acquired a new position in shares of Integer during the 4th quarter worth about $2,195,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Integer by 3.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,904 shares of the medical equipment provider's stock valued at $782,000 after acquiring an additional 180 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Integer by 1.4% in the fourth quarter. HighTower Advisors LLC now owns 12,207 shares of the medical equipment provider's stock worth $1,618,000 after acquiring an additional 166 shares during the last quarter. Swiss National Bank raised its stake in Integer by 0.8% in the 4th quarter. Swiss National Bank now owns 65,900 shares of the medical equipment provider's stock valued at $8,733,000 after purchasing an additional 500 shares during the last quarter. Finally, Royce & Associates LP lifted its holdings in Integer by 31.9% in the 4th quarter. Royce & Associates LP now owns 61,759 shares of the medical equipment provider's stock valued at $8,184,000 after purchasing an additional 14,919 shares in the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Trading Down 1.9%

Shares of ITGR stock traded down $2.13 during trading hours on Friday, reaching $112.51. 463,003 shares of the stock traded hands, compared to its average volume of 390,078. The business has a fifty day moving average price of $119.65 and a 200 day moving average price of $124.39. Integer Holdings Corporation has a 1-year low of $104.93 and a 1-year high of $146.36. The company has a quick ratio of 2.14, a current ratio of 3.40 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $3.93 billion, a PE ratio of 53.32, a PEG ratio of 0.97 and a beta of 0.98.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The business had revenue of $437.39 million during the quarter, compared to analyst estimates of $428.51 million. Integer had a return on equity of 11.95% and a net margin of 4.38%. Integer's quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the company earned $1.14 earnings per share. On average, equities research analysts forecast that Integer Holdings Corporation will post 6.01 EPS for the current year.

Insider Transactions at Integer

In related news, CEO Joseph W. Dziedzic sold 338,975 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $123.17, for a total value of $41,751,550.75. Following the completion of the transaction, the chief executive officer directly owned 47,000 shares in the company, valued at approximately $5,788,990. The trade was a 87.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald J. Spence sold 14,739 shares of the company's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the completion of the transaction, the director directly owned 18,781 shares of the company's stock, valued at approximately $2,260,856.78. The trade was a 43.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 362,434 shares of company stock valued at $44,577,115 in the last three months. 2.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on ITGR shares. Wall Street Zen raised shares of Integer from a "sell" rating to a "hold" rating in a research report on Monday, May 19th. KeyCorp reduced their price target on Integer from $154.00 to $145.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. Truist Financial set a $150.00 price objective on Integer and gave the stock a "buy" rating in a research report on Friday, April 25th. Raymond James Financial raised their target price on shares of Integer from $145.00 to $150.00 and gave the company an "outperform" rating in a report on Friday, April 25th. Finally, Citigroup upgraded shares of Integer from a "hold" rating to a "strong-buy" rating and boosted their price target for the stock from $133.00 to $140.00 in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Integer currently has a consensus rating of "Moderate Buy" and an average target price of $146.25.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.